Navigation Links
Mesa Labs Reports Higher Quarterly Sales and Earnings

LAKEWOOD, Colo., Feb. 10 /PRNewswire-FirstCall/ -- Mesa Laboratories, Inc. (Nasdaq: MLAB) today reported significantly higher sales and earnings for both its fiscal third quarter and nine months ended December 31, 2008.


  • Third quarter revenue increases 16%
  • Third quarter net income increases 8%
  • Third quarter diluted EPS increases 12%

For the third quarter of fiscal 2009, net sales increased 16 percent to $5,337,000 from $4,614,000 in the same quarter last year. Net income for the quarter increased eight percent to $1,216,000 or $.38 per diluted share compared to $1,121,000 or $.34 per diluted share one year ago.

For the first nine months of fiscal 2009, net sales increased 17 percent to $16,071,000 from $13,768,000 in the same period last year. Net income for the first nine months increased five percent to $3,586,000 or $1.11 per diluted share compared to $3,415,000 or $1.04 per share one year ago.

"Mesa's business continued to perform well in the third quarter of fiscal 2009, driven primarily by excellent sales growth of the Raven and Medical product lines," said John J. Sullivan, President and Chief Operating Officer. "While sales for the DataTrace line were flat this quarter compared to last year, year-to-date this product line is exhibiting double-digit growth. DataTrace sales have always been more cyclical and it is not uncommon to see periods of high growth followed by a period of modest decline for these products. Overall however, we are encouraged by the long term incremental growth of the DataTrace line, driven partially by the positive impact of our new, market-leading RF technology introduced earlier this year," continued John Sullivan. "Looking ahead we are faced with a very challenging economic environment that is likely to test Mesa's ability to continue to deliver sales and net income growth. However, we are committed to executing our three-pronged strategy of improving our distribution channels, increasing the flow of new products, and seeking strategic acquisitions as the keys to enhancing long term shareholder value."

During the third quarter and first nine months of fiscal 2009, sales of the Company's medical products and services increased 23 and 18 percent, respectively, compared to the prior year periods. For both the quarter and the nine month period, strong increases in shipments of the meter products, standard solutions and parts and service contributed to the total increase over prior year.

For the quarter, DataTrace sales decreased less than one percent compared to the same period last year, while sales increased 14 percent for the nine month period compared to the same period last year. During the quarterly period, sales of the new Micropack RF products were offset by a decrease in rental and associated service revenues along with a small decrease in total Micropack III sales. The increase for the nine month period is attributable chiefly to higher Micropack RF and Micropack III revenues compared to prior year.

During the third quarter and first nine months of fiscal 2009 sales of Raven biological indicator products increased 25 percent and 17 percent, respectively, compared to the prior year period. The increase in Raven sales for both the quarter and nine month periods was due to increases in sales of the biological indicator and chemical indicator products.

Profitability for the third quarter and nine month periods of fiscal 2009 was up compared to the prior fiscal year due chiefly to the increase in revenues. For the quarter, net income increased eight percent but diluted earnings per share increased by 12 percent. For the first nine month period, net income increased five percent while earnings per diluted share increased by seven percent for the period.

During the first nine months of fiscal 2009, the Company repurchased 5,315 shares of our common stock under a previously announced buyback plan for approximately $106,000. In addition, the Company has a remaining commitment of approximately $236,000 for automation of certain manufacturing processes for its Raven line of biological indicators. This equipment began limited production during December and final payment against this commitment is expected during the fourth quarter.

Mesa Laboratories develops, acquires, manufactures and markets electronic instruments and disposables for industrial, pharmaceutical and medical applications.

This news release contains forward-looking statements which involve risks and uncertainties. The Company's actual results could differ materially from those in any such forward-looking statements. Additional information concerning important factors that could cause results to differ materially from those in any such forward-looking statement is contained in the Company's Annual Report on Form-10K for the year ended March 31, 2008 as filed with the Securities and Exchange Commission, and from time to time in the Company's other reports on file with the Commission.

                                 FINANCIAL SUMMARY

                                 Quarter Ended          Nine Months Ended
                                  December 31             December 31
                               2008         2007        2008         2007
    Net Sales               $5,337,000  $4,614,000 $16,071,000 $13,768,000
    Cost of Goods            1,903,000   1,527,000   5,786,000   4,494,000
    Gross Profit             3,434,000   3,087,000  10,285,000   9,274,000
    Operating Expense        1,550,000   1,399,000   4,770,000   4,150,000
    Operating Income         1,884,000   1,688,000   5,515,000   5,124,000
    Other (Income) & Expense   (16,000)    (54,000)    (79,000)   (150,000)
    Earnings Before Taxes    1,900,000   1,742,000   5,594,000   5,274,000
    Income Taxes               684,000     621,000   2,008,000   1,859,000
    Net Income              $1,216,000  $1,121,000  $3,586,000  $3,415,000

    Earnings Per Share
     (Basic)                      $.38        $.35       $1.13       $1.08
    Earnings Per Share
     (Diluted)                    $.38        $.34       $1.11       $1.04

    Average Shares
     (Basic)                 3,182,000   3,165,000   3,177,000   3,168,000
    Average Shares
     (Diluted)               3,229,000   3,292,000   3,240,000   3,285,000

    BALANCE SHEETS          (Unaudited)
                              Dec. 31    March 31
                               2008         2008
    Cash and Short-term
     Investments            $7,962,000  $5,770,000
    Other Current Assets     9,356,000   8,641,000
    Total Current Assets    17,318,000  14,411,000
    Property and Equipment   3,791,000   3,488,000
    Other Assets             7,112,000   7,634,000

    Total Assets           $28,221,000 $25,533,000

    Liabilities             $1,581,000  $1,794,000
    Stockholders' Equity    26,640,000  23,739,000

    Total Liabilities
     and Equity            $28,221,000 $25,533,000


    Luke R. Schmieder; CEO-Chairman of the Board of Directors
    John J. Sullivan, President-COO
    Steven W. Peterson; VP Finance-CFO
    Mesa Laboratories, Inc.

SOURCE Mesa Laboratories, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Hanger Orthopedic Group, Inc. Reports $0.26 Pro Forma EPS on 8.6% Sales Growth for the Fourth Quarter 2008
2. Sharps Compliance Corp. Reports Second Quarter Fiscal 2009 Results
3. NADP Study Reports Dramatic Increase in Value of Dental Benefits
4. The Female Health Company Reports First Quarter Operating Results, as Gross Profit Margins Widen on Increasing Sales of FC2 Female Condom(R)
5. Cynosure Reports Financial Results for the Fourth Quarter and Full Year 2008
6. Allied Healthcare Reports Second Quarter Loss
7. Immtech Reports Fiscal Third Quarter 2009 Results
8. Misonix Reports Earnings and Increased Revenues for the Three and Six Months Ended December 31, 2008
9. ViroPharma Reports Results of Phase 3 Clinical Trial for Maribavir in Bone Marrow Transplant Patients
10. Chindex International, Inc. Reports Third Quarter FY 2009 Financial Results
11. Bioniche Reports Fiscal 2009 Second Quarter
Post Your Comments:
(Date:6/26/2016)... (PRWEB) , ... June 26, 2016 , ... ... fertility once they have been diagnosed with endometriosis. These women need a treatment ... also require a comprehensive approach that can help for preservation of fertility and ...
(Date:6/25/2016)... ... 25, 2016 , ... "With 30 hand-drawn hand gesture animations, FCPX users can ... CEO of Pixel Film Studios. , ProHand Cartoon’s package transforms over 1,300 hand-drawn ... X . Simply select a ProHand generator and drag it above media or text ...
(Date:6/25/2016)... ... 25, 2016 , ... On Friday, June 10, Van Mitchell, Secretary of the ... to iHire in recognition of their exemplary accomplishments in worksite health promotion. , The ... Health & Wellness Symposium at the BWI Marriott in Linthicum Heights. iHire was one ...
(Date:6/24/2016)... ... June 24, 2016 , ... June 19, 2016 is World Sickle Cell ... pain and the benefits of holistic treatments, Serenity Recovery Center of Marne, ... Cell Disease. , Sickle Cell Disease (SCD) is a disorder of the red blood ...
(Date:6/24/2016)... ... June 24, 2016 , ... Dr. Amanda Cheng, ... treatment. Dr. Cheng has extensive experience with all areas of orthodontics, including robotic ... osteogenic orthodontics. , Micro-osteoperforation is a revolutionary adjunct to orthodontic treatment. It ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... KNOXVILLE, Tenn. , June 24, 2016 /PRNewswire/ ... market providing less invasive and more durable cerebrospinal ... million in funding.  The Series-A funding is led ... the Lighthouse Fund, and other private investors.  Arkis, ... less-invasive neurosurgical instrumentation and the market release of ...
(Date:6/23/2016)... Research and Markets has announced the addition of ... report to their offering. ... kidney failure, it replaces the function of kidneys by removing ... thus the treatment helps to keep the patient body,s electrolytes ... Increasing number of ESRD patients & substantial healthcare expenditure ...
(Date:6/23/2016)... 2016 Research and Markets has ... by Type (Organic Chemical (Sugar, Petrochemical, Glycerin), Inorganic Chemical), ... Parenteral) - Global Forecast to 2021" report to ... The global pharmaceutical excipients market is projected to reach ... 6.1% in the forecast period 2016 to 2021. ...
Breaking Medicine Technology: